Pregabalin Capsule
Product Images NDC 70518-3974

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3974). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Pregabalin 25 mg oral capsules by RemedyRepack Inc. The label indicates a quantity of 30 capsules in the package. The label also shows NDC 70518-3974-00, manufacturer Arneck Pharma, and includes storage instructions and a caution to keep the medication out of reach of children.*

FDA Label Image

10 (Pregabalin Capsules 1)

This image shows a formula for calculating creatinine clearance (CLCr). The formula is expressed as [(140 - age in years) x weight in kilograms] divided by [72 x serum creatinine in mg/dL], with a multiplication factor of 0.85 for female patients. It is a mathematical expression related to kidney function assessment.*

FDA Label Image

Lk (Pregabalin Capsules 10)

A bar chart comparing responder rates (%) among three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The chart shows increasing responder rates from placebo (22.6%) to 2.5 mg/kg/day (29.1%) and highest at 10 mg/kg/day (40.6%). Sample sizes (N) are shown below each group.*

FDA Label Image

9 (Pregabalin Capsules 11)

A line chart showing the percent of patients improved against percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, 600 mg, and placebo. The chart compares the effectiveness of different daily doses of Pregabalin and placebo in improving patient pain levels.*

FDA Label Image

10 (Pregabalin Capsules 12)

A Kaplan-Meier survival curve chart comparing the percentage of subjects without LTR (loss to response) over a period of 180 days between two groups labeled Pregabalin and Placebo. The y-axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group consistently shows a higher percentage of subjects without LTR compared to the Placebo group throughout the duration.*

FDA Label Image

11 (Pregabalin Capsules 13)

A line graph comparing the percent of subjects improved from baseline to week 12, showing data for Pregabalin versus placebo. The x-axis represents percent improvement, while the y-axis shows the percent of subjects improved. Pregabalin demonstrates a higher improvement rate compared to placebo throughout the range.*

FDA Label Image

12 (Pregabalin Capsules 14)

A comparative line chart showing the percentage of subjects improved from baseline to Week 16 BOCF for Pregabalin and placebo groups. The x-axis represents the percent improved from baseline to Week 16, ranging from 0 to 100%. The y-axis represents the percent of subjects improved, ranging from 0 to 100%. Two lines depict the progression of improvement for Pregabalin and placebo over the range.*

FDA Label Image

Df (Pregabalin Capsules 2)

Chemical structure of pregabalin showing its molecular arrangement with functional groups including an amino group and a carboxyl group.*

FDA Label Image

1 (Pregabalin Capsules 3)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved across four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph shows trends of pain improvement for these different dosages of Pregabalin and placebo over a range of improvement percentages.*

FDA Label Image

2 (Pregabalin Capsules 4)

A line chart comparing the percent of patients improved against the percent improvement in pain from baseline. Two curves are shown: one for Pregabalin 100 mg three times a day and one for placebo, illustrating patient response differences over a range of pain improvement percentages.*

FDA Label Image

3 (Pregabalin Capsules 5)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, illustrating patient response across these dosing regimens and placebo over a range of pain improvement percentages.*

FDA Label Image

4 (Pregabalin Capsules 6)

A line graph showing percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The graph displays trends of patient improvement over varying levels of pain relief percentages.*

FDA Label Image

5 (Pregabalin Capsules 7)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo. The graph illustrates the distribution of patient improvement across these treatments over a range from 0 to 100 percent.*

FDA Label Image

6 (Pregabalin Capsules 8)

Bar chart showing responder rates (%) in two studies labeled Study E1 and Study E3. Study E1 compares placebo and different doses of a drug administered twice daily (BID) at 50 mg to 600 mg/day, with responder rates increasing from 14% (placebo) to 51% (600 mg/day). Study E3 compares placebo, 600 mg/day twice daily (BID), and 600 mg/day three times daily (TID), with responder rates of 9%, 43%, and 40% respectively. Sample sizes (N) are indicated for each group.*

FDA Label Image

7 (Pregabalin Capsules 9)

A line graph displaying the median percentage reduction in seizures from baseline versus dose in mg/day for four different studies of Pregabalin. The dose ranges from 0 (placebo) to 600 mg/day, with data points marked for Studies E1 BID, E2 TID, E3 BID, and E3 TID. Significant p-values are noted at various dose levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.